Exagen (NASDAQ:XGN) Given Buy Rating at BTIG Research

Exagen (NASDAQ:XGN)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research note issued on Wednesday, Benzinga reports. They presently have a $9.00 price objective on the stock. BTIG Research‘s price objective points to a potential upside of 71.10% from the stock’s previous close.

A number of other research analysts also recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of Exagen from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. B. Riley Financial began coverage on shares of Exagen in a research report on Friday, September 11th. They set a “buy” rating and a $12.00 target price for the company. Finally, TD Cowen raised their target price on shares of Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.12.

Exagen Trading Down 25.9%

XGN opened at $5.26 on Wednesday. The business’s 50-day moving average is $7.88 and its two-hundred day moving average is $5.13. Exagen has a 1 year low of $2.59 and a 1 year high of $9.73. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 1.96.

Exagen (NASDAQ:XGN) last announced its earnings results on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $18.42 million during the quarter, compared to the consensus estimate of $18.34 million. Exagen had a negative return on equity of 104.46% and a negative net margin of 26.61%. Sell-side analysts anticipate that Exagen will post -0.69 EPS for the current fiscal year.

Insider Activity

In other Exagen news, CEO John Aballi sold 34,294 shares of the stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $7.87, for a total value of $269,893.78. Following the completion of the sale, the chief executive officer directly owned 805,540 shares in the company, valued at approximately $6,339,599.80. This trade represents a 4.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Jorey Chernett purchased 14,000 shares of the stock in a transaction on Monday, October 19th. The stock was acquired at an average cost of $7.46 per share, with a total value of $104,440.00. Following the acquisition, the insider owned 2,618,540 shares of the company’s stock, valued at approximately $19,534,308.40. This represents a 0.54% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 29,585 shares of company stock worth $195,682 over the last ninety days. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Exagen

A number of institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LP purchased a new stake in Exagen during the 2nd quarter worth approximately $52,000. Penbrook Management LLC purchased a new position in shares of Exagen in the third quarter worth $92,000. Calamos Advisors LLC purchased a new position in shares of Exagen in the third quarter worth $94,000. Bank of New York Mellon Corp purchased a new position in shares of Exagen in the second quarter worth $97,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Exagen by 137.4% during the first quarter. Dimensional Fund Advisors LP now owns 62,571 shares of the company’s stock worth $188,000 after buying an additional 36,213 shares during the period. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Key Exagen News

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Third-quarter revenue rose 7% year over year to $18.4 million, slightly exceeding estimates. For the first nine months, revenue increased 11%, net loss narrowed 12%, and adjusted EBITDA loss improved by more than 30%. Exagen third-quarter results
• Positive Sentiment: Major shareholder Jorey Chernett bought 7,085 shares on Nov. 10 and 8,500 on Nov. 9, more than offsetting his 11,265-share sale on Nov. 6. The net buying is a modest confidence signal. Chernett’s share purchases
• Positive Sentiment: Exagen said it remains on track to launch its myositis offering in early 2027, potentially broadening its diagnostics platform.
• Neutral Sentiment: The company reaffirmed 2026 revenue guidance of $72 million to $75 million, a range that includes the roughly $73.9 million analyst consensus, so it was not a forecast upgrade.
• Negative Sentiment: Quarterly loss was $0.25 per share, worse than analyst expectations of roughly $0.18–$0.19. Operating expenses rose, widening the operating loss to $4.4 million from $3.1 million a year earlier; quarterly adjusted EBITDA loss also edged wider. Cash of $28.1 million was lower than the $35.7 million reported a year earlier, keeping profitability and cash use in focus. Q3 earnings report

Exagen Company Profile

Exagen Inc. is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time. Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.